- Home
- Publications
- Publication Search
- Publication Details
Title
Marginal Zone Lymphoma: State-of-the-Art Treatment
Authors
Keywords
-
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 20, Issue 12, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-05
DOI
10.1007/s11864-019-0687-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
- (2019) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
- (2019) Ian W. Flinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Choosing the right pharmacotherapy for non-Hodgkin’s lymphoma: does one size fit all?
- (2019) Taha Al Juhaishi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Lenalidomide plus rituximab (R 2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial
- (2019) Melody R. Becnel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
- (2019) Andres Forero-Torres et al. BLOOD
- Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
- (2018) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
- (2018) S de Vos et al. ANNALS OF ONCOLOGY
- Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study
- (2018) Emilio Iannitto et al. BRITISH JOURNAL OF HAEMATOLOGY
- Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution
- (2018) Juan Pablo Alderuccio et al. JOURNAL OF CLINICAL ONCOLOGY
- IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL)
- (2017) M. Herold et al. HEMATOLOGICAL ONCOLOGY
- Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
- (2017) Emanuele Zucca et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance
- (2016) E. Zucca et al. BLOOD
- Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402
- (2016) Michael E. Williams et al. BRITISH JOURNAL OF HAEMATOLOGY
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
- (2016) Laurie H Sehn et al. LANCET ONCOLOGY
- Histologic transformation in marginal zone lymphomas
- (2015) A. Conconi et al. ANNALS OF ONCOLOGY
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
- (2015) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
- (2014) I. W. Flinn et al. BLOOD
- Phase II study of90Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma
- (2014) Izidore S. Lossos et al. LEUKEMIA & LYMPHOMA
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial
- (2014) Antonio Salar et al. Lancet Haematology
- Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma
- (2012) Andreas Heilgeist et al. CANCER
- Chlamydophila PsittaciEradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial
- (2012) Andrés J.M. Ferreri et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study
- (2011) Hye Jin Kang et al. ANNALS OF HEMATOLOGY
- Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy
- (2010) Jayant S. Goda et al. CANCER
- A phase II study of bortezomib in patients with MALT lymphoma
- (2009) M. Troch et al. HAEMATOLOGICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started